检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《中国医学创新》2009年第28期9-11,共3页Medical Innovation of China
摘 要:目的探讨新疆维吾尔族乳腺癌患者组织中CerbB-2的表达及与ER、PR表达的关系及临床意义。方法采用免疫组化对笔者所在医院100例维族乳腺癌组织进行CerbB-2及ER(雌激素受体)、PR(孕激素受体)测定,分析它们之间的表达及其临床意义。结果 CerbB-2阳性表达者占34%,ER、PR阳性率分别为52%、50%,CerbB-2阳性率在ER阳性组为19.2%,在ER阴性组为50%(P=0.0012,r=-0.325),CerbB-2阳性率在PR阳性组为16%,在PR阴性组为52%(P=0.0001,r=-0.38);CerbB-2阳性表达与肿瘤大小呈正相关(P<0.05),与临床分期呈正相关(P<0.01),与雌激素、孕激素受体呈负相关(P<0.01),与年龄、淋巴结转移无关。结论维吾尔族乳腺癌组织CerbB-2的表达与肿瘤大小及临床病理分级呈正相关,是预后较差的指标,CerbB-2的表达与ER、PR阳性表达呈负相关,CerbB-2是判断维吾尔族乳腺癌预后的有效指标,联合检测CerbB-2、ER和PR可以指导临床综合治疗,评判预后。Objective To investigate breast cancer in Xinjiang Uygur CerbB -2 expression and ER, PR expression and clinical significance of the relationship. Methods Immunohistochemical method used in our hospital 100 cases of breast cancer organizations Uygnrs CerbB - 2 and ER, PR Measurement, analysis of their expression and clinical significance. Results The positive expression of CerbB - 2 accounted for 34% , of ER and PR were 52% and 50% ,respectively, CerbB - 2 positive rate of ER-positive group were 19.2%, and 50% in ER-negative group (P=0.0012, r= -0.325), CerbB-2 - positive rate of PR - positive group was 16%, and 52% in PR - negative group ( P = 0.0001, r = - 0.38 ) ; CerbB - 2 ex- pression and tumor size was positively correlated ( P〈0.05 ), CerbB - 2 expression and clinical stage was positively correlated ( P 〈0.01), CerbB - 2 expression and expression of estrogen receptor was negative correlation ( P 〈 0.01), with age, lymph node metastasis. Conclusion High CerbB -2 expression and ER, PR positive expression was a negative correlation. CerbB -2 is to determine an effective indicator of prognosis of breast cancer, Combined detection of CerbB - 2, ER and PR can guide the clinical treatment and prognosis evaluation.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15